Understanding how a specific protein affects immune response in certain cancers caused by papillomavirus
Official title: Investigating the mechanism of K17-mediated immunosuppression in papillomavirus-induced cancers
Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-10885642 · Data updated 2026-11-12
This study is looking at how a protein called keratin 17 helps HPV-related cancers hide from the immune system, with the goal of finding new ways to improve treatments for patients battling these types of cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $193,616 |
| NIH project number | 1K22CA282264-01A1 |
| Project ID | NIH-10885642 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with HPV-related cancers, such as anal or cervical cancer.
✕Less likely to help
Patients with cancers not associated with HPV or those who do not have a significant immune response may not benefit from this research.
What this research studies
This research investigates how the protein keratin 17 (K17) contributes to immune suppression in cancers associated with human papillomavirus (HPV). By using a mouse model of papillomavirus infection, the study aims to uncover the molecular mechanisms that allow K17 to help the virus persist and evade the immune system. The findings could lead to new therapeutic targets that enhance cancer immunotherapy treatments for patients with HPV-related cancers. The research focuses on understanding the tumor microenvironment and how it can be manipulated to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with HPV-related cancers.
How similar studies have gone: Previous research has shown promising results in understanding immune suppression mechanisms in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Henry Ford Health + Michigan State University Health Sciences
East Lansing, United States Active
Researchers
- Principal investigator: Wang, Wei — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Wang, Wei
Related research
Other NIH-funded projects on the same topics.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
-
AHR-driven immunosuppression in glioblastoma and new therapeutic targets
A personalized cancer study aims to understand why glioblastoma suppresses the immune system and to find ways to boost anti-tumor immunity in patients with this brain tumor.
-
Fibroblast-made GABA fuels PDAC immune suppression
In people with pancreatic cancer, this study explores how a specific cell type in the tumor environment uses a brain-like chemical (GABA) to dampen immune attack against the cancer.
-
Biomarker-guided reduction of immunosuppression after liver transplant
A multicenter trial tests whether using blood biomarkers to guide tapering of immunosuppression in adults with liver transplants can keep people healthy while lowering drug exposure.
-
Understanding and Overcoming T cell Immunosuppression in Glioblastoma (GBM)
A large research program is looking at how glioblastoma tumors weaken immune responses and how to boost immune cells to fight GBM.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.